Lisinopril

Drug Profile

Lisinopril

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Transparency Life Sciences
  • Class Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cardiovascular disorders
  • No development reported Multiple sclerosis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis(Adjunctive treatment) in USA
  • 08 Sep 2014 Transparency Life Sciences receives SBIR grant from the National Center for Advancing Translational Sciences for lisinopril development in Multiple Sclerosis
  • 18 Dec 2012 Preclinical trials in Multiple sclerosis (adjunctive treatment) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top